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PKCaA-disintegrin and metalloproteinase 10 (ADAM10) is involved in the generation of amyloid-b (Ab)
during amyloid precursor protein (APP) processing, and has a protective effect against Ab neurotoxi-
city. We explored how metallothionein-III (MT-III) is regulated in the non-amyloidogenic pathway
to generate soluble APPa (sAPPa). MT-III increased sAPPa levels and reduced Ab peptide levels,
but did not affect ADAM10 expression. However, MT-III increased the activity of ADAM10. MT-III-
induced sAPPa secretion, and Ab peptide formation was blocked by speciﬁc inhibitors of furin, pro-
protein convertase7 (PC7), and PKCa. These results demonstrate that MT-III increases the amount of
active ADAM10 in association with furin, PC7 and PKCa.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction The amyloid precursor protein (APP) can be processed by twoMetallothioneins (MTs) are low-molecular-weight (6–7 kDa),
cysteine-rich proteins with a high metal content. They function
as intracellular metal-binding proteins that are expressed in a wide
range of eukaryotic species, from yeasts to mammals [1]. The MT-I
and II subtypes are expressed mainly in astrocytes and microglia
[2,3], while the MT-III subtype is expressed predominantly in neu-
ronal cells [4]. MT-III expression is decreased in Alzheimer’s
disease (AD) [5] and upregulated following brain injury, such as
a stab wound [6]. We demonstrated previously that MT-III pro-
vides neuronal protection by activating nuclear factor-jB (NF-jB)
through the TrkA/phosphatidylinositol-3 kinase (PI3K)/Akt signal-
ling pathway [7]. Although previous studies have suggested that
MT-III may have a neuroprotective role, the underlying mechanism
in AD remains unclear.alternative, mutually exclusive post-translational pathways;
amyloidogenic and non-amyloidogenic [8]. APP proteolysis is the
fundamental process for the production of amyloid-b (Ab) peptides
in AD pathology [9–12]. For the generation of Ab, APP is processed
through the amyloidogenic pathway by b- and c-secretases. Ab
peptides of 40–42 amino acids in length are constituents of senile
plaques in AD brains and exert direct or indirect neurotoxic effects
[13]. In contrast, in the alternative non-amyloidogenic pathway,
APP is cleaved within the Ab peptide sequence at the cell surface
by a-secretases, leading to the release of a soluble N-terminal frag-
ment (soluble amyloid precursor protein a (sAPPa)) into the extra-
cellular space [1–3]. Since sAPPa and Ab peptides are formed
through two mutually exclusive pathways, activation of the
a-secretase prevents the formation of Ab peptides [4].
Several reports have implicated members of the A-disintegrin
and metalloproteinase (ADAM) family, a family of zinc metallopro-
teinases that includes ADAM9, -10, and -17, as putative a-secretase
candidates [14–16]. ADAM10 cleaves APP-derived peptides at the
a-secretase cleavage site, and expression of mutated ADAM10 sig-
niﬁcantly decreases endogenous a-secretase activity. It has been
reported that ADAM10 has many properties of a physiologically
relevant a-secretase. For example, ADAM10 is required for activa-
tion of the non-amyloidogenic pathway. Furthermore, ADAM10
possesses a proprotein convertase recognition sequence between
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tic cleavage by PC7 and/or furin may be important for proenzyme
activation. Several studies have explored the therapeutic potential
of compounds that promote non-amyloidogenic processing of APP
[17]. In the present study, we investigated the mechanism of MT-III
regulation of APP. We further showed that sAPPa secretion is
required for activation of a-secretase in the non-amyloidogenic
pathway.
2. Materials and methods
2.1. Materials
Reagents used in this study were purchased from the following
sources: Dulbecco’s modiﬁed Eagle’s medium (DMEM), OPTI-MEM,
foetal bovine serum, and penicillin–streptomycin solution from
Gibco-BRL/Life Technologies (Grand Island, NY); L-Glutamine and
Hygromysin B from Sigma–Aldrich (St. Louis, MO); Trichloroacetic
acid (TCA) and acetone from Fluka (Buchs, Switzerland); phospho-
PKCa/bII (Thr638/641), PKCa, HRP-linked anti-rabbit IgG and HRP-
linked anti-mouse IgG from Cell Signalling Technology (Beverly,
MA); furin from Abcam (La Jolla, CA); PC7/8, ADAM10, amyloid-b
and b-actin from Santa Cruz Biotechnology (Santa Cruz, CA); and
Western blotting detection reagents (ECL) from Amersham Phar-
macia Biotech (Piscataway, NJ). All chemicals were of the highest
commercial grade available.
2.2. Cell culture
The mouse neuroblastoma Neuro2A (N2a) Swedish APP cells
were kindly provided by Dr. Kyung-sik Song (College of Pharmacy,
Kyungpook National University, Daegu, Korea). Cells were cultured
in 45% DMEM, 55% Opti-MEM (Gibco), 10% heat-inactivated foetal
bovine serum, 100 U/ml penicillin, 100 mg/ml streptomycin, 1%
Glutamine, and 0.09% Hygromysin B (Sigma–Aldrich, St. Louis,
MO) in a humidiﬁed atmosphere containing 5% CO2 in air at 37 C.
2.3. Expression and puriﬁcation of human MT-III
The method of MT-III expression and puriﬁcation has been
described previously [7]. Brieﬂy, MT-III cDNA was inserted into
pGEX-4T, and MT-III protein was then expressed in Escherichia coli
BL21 and puriﬁed by afﬁnity chromatography on glutathione-
Sepharose 4B.
2.4. TCA precipitation
Culture medium (1 ml) was added to 250 ll of 100% trichloroa-
cetic acid (TCA) (Fluka, Buchs, Switzerland). The mixture was incu-
bated for 10 min at 4 C and centrifuged at 10000g at 4 C for
5 min. The supernatant was removed and 200 ll of 90% ice-cold
acetone (Fluka) were added to wash the pellet. The washing step
was repeated three times. The acetone-containing supernatant
was removed and the pellet was air-dried.
2.5. Western blot analysis
After treatment, cells were collected and washed with phos-
phate-buffered saline (PBS), lysed on ice for 30 min in 100 ll of
lysis buffer, and centrifuged at 12000 rpm for 30 min. The super-
natants were collected and the protein concentrations were deter-
mined using a BCA protein assay kit (Pierce, Rockford, IL). Aliquots
of the lysates (40 lg of protein) were boiled for 5 min then sub-
jected to 10% SDS–PAGE. Proteins in the gels were then transferred
to nitrocellulose membranes, which were incubated with primaryantibodies or mouse monoclonal anti-b-actin antibodies. The
membranes were then further incubated with secondary anti-
mouse or -rabbit antibodies. Finally, the protein bands were
detected using an enhanced chemiluminescence Western blotting
detection kit (Pierce).
2.6. Real-time PCR
Total RNA was isolated from MT-III-treated cells using an RNA
isolation kit (Takara Shuzo, Kyoto, Japan) according to the manu-
facturer’s protocol. The quality of RNA was conﬁrmed based on a
ratio of >1.8 for the optical densities at 260 and 280 nm. cDNA
synthesis and reverse transcriptase polymerase chain reaction
(RT-PCR) was performed following standard protocols. PCR product
formation was continuously monitored during PCR using Sequence
Detection System software, version 1.7 (Applied Biosystems, Foster
City, CA). Accumulated PCR products were detected directly by
monitoring the increase in reporter dye (SYBR) signal. The primers
used in this study are provided in Supplementary Table 1. The
quantity of each transcript was calculated as described in the
instrument manual and was normalised to the amount of
b-actin (a housekeeping gene).
2.7. Quantiﬁcation of Ab levels using ELISA
The levels of secreted Ab were quantiﬁed using a sandwich
ELISA as described previously, with minor modiﬁcations [18,19].
Brieﬂy, culture medium was collected, treated with protease inhi-
bitors from Calbiochem (La Jolla, CA), and cleared by centrifugation
(13000g, 5 min, 4 C). Supernatant (100 ll) was used for Ab
quantiﬁcation based on ﬂuorescent sandwich ELISA. All ELISA
experimental data were obtained on ﬁve separate days. The sub-
strate was used to monitor Ab levels by means of the change in
absorption at 450 nm.
2.8. Statistical analysis
All experiments were repeated in at least triplicate. One-way
analysis of variance (ANOVA) was used to determine the
signiﬁcance of differences between treatment groups. The New-
man–Keuls test was used for multi-group comparisons. Statistical
signiﬁcance was accepted for P-values <0.01.
3. Results
3.1. MT-III has an effect on process of APP processing
We examined the metabolism of soluble a-secretase released
APP ectodomain (sAPPa) by MT-III. We also examined whether
sAPPawas present in Neuro2A (N2a) Swedish APP cells and absent
in N2a cells (Supplementary Fig. 1), and whether MT-III affected
sAPPa levels. However, we haven’t still yet found of endogenous
extracellular MT-III levels in neuronal cells. As shown in Fig. 1A,
MT-III signiﬁcantly increased sAPPa levels. Treatment of N2a
Swedish APP cells for 24 h with MT-III increased sAPPa levels in
a dose-dependent manner (Fig. 1B). We also analysed Ab levels
using ELISA (Fig. 1C) and examined whether MT-III affected the
mRNA levels of ADAM10 and BACE1 using real-time PCR. We found
that MT-III did not affect the mRNA levels of ADAM10 and BACE1
(Supplementary Fig. 2). In addition, the precursor form of ADAM10
was not affected by MT-III treatment, showing an expression pat-
tern similar to that of ADAM10. However, MT-III signiﬁcantly
increased the active ADAM10 level in N2a Swedish APP cells
(Fig. 1D). These results indicated that MT-III regulates ADAM10
conversion to its active form in N2a Swedish APP cells.
A C
D
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Fig. 1. MT-III has an effect on process of non-amyloidogenic processing. (A) Cells were pre-treated with 100 pM of MT-III for 0, 6, 12, 18 or 24 h. The level of sAPPa secretion
was analysed by Western blotting of the culture supernatant. (B) Cells were pre-treated with 0, 1, 10 or 100 pM MT-III for 24 h. The level of sAPPa secretion was analysed by
Western blot of the culture supernatant. (C) Ab levels were analysed using ELISA of the culture supernatant. (D) ADAM10 expression was analysed by Western blotting of cell
lysates. Densitometry analysis shows the band density ratio of active ADAM10 to precursor ADAM10. All experiments were performed in triplicate, and the means and S.D.s
are shown. ⁄P < 0.01; signiﬁcantly different from the control.
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Overexpression of PC7 and furin increased levels of the active
form of ADAM10, resulting in enhanced a-secretase-mediated pro-
cessing of APP [20]. Thus, we examined whether MT-III affected the
expression of PC7 and furin. We found that MT-III increased the
mRNA levels of PC7 and furin (Fig. 2A and B). In addition, MT-III
increased the protein levels of furin and PC7 (Fig. 2C). We next
evaluated whether MT-III played a role in the conversion of
ADAM10 through furin and PC7. Histidine-rich antibacterial
human salivary peptide histatin 5 is known to inhibit furin and
PC7 [21,22]. We ﬁrst measured the levels of active ADAM10 and
sAPPa in N2a Swedish APP cells. As shown in Fig. 3A and B, inhibi-
tion of PC7 and furin activity by pre-treatment with histatin 5
blocked active ADAM10 generation and decreased sAPPa levels.
We next conﬁrmed that MT-III-induced Ab increases were inhib-
ited by histatin 5 (Fig. 3C). These results demonstrated that
MT-III regulates conversion to active ADAM10 through furin and
PC7.
3.3. MT-III increases PKCa expression
PKC activation decreases Ab production in various cell systems
[23]. Furthermore, overexpression of PKCa increases sAPPa secre-
tion [24]. Thus, we determined whether MT-III affects the phos-
phorylation and expression of PKCa. We found that MT-III
weakly increased the phosphorylation of PKCa for 15–60 min
(Supplementary Fig. 4). In addition, MT-III signiﬁcantly increased
PKCa levels after 24 h (Fig. 4A and B). However, MT-III did not
increase the PKCb and PKCc levels (Supplementary Fig. 3). Accord-
ingly, we determined whether MT-III affected the phosphorylationand expression of PKCa during the secretion of sAPPa. We found
that MT-III increased the levels of phosphorylated PKCa and sAPPa
(Fig. 4B and D). Inhibition of phospho-PKCa by pre-treatment with
Gö6976 blocked the phosphorylation of PKCa and decreased sAPPa
levels (Fig. 4C and D). We then conﬁrmed that MT-III-induced Ab
levels were inhibited by Gö6976 (Fig. 4E). These results suggested
that MT-III is involved in the secretion of sAPPa through PKCa.
3.4. Role of MT-III in non-amyloidogenic processing
At this time, MT-III is known to play a role in the generation of
active ADAM10 in the non-amyloidogenic pathway during APP
processing. Histatin 5 is a known inhibitor of furin and PC7 activity,
which blocks the generation of active ADAM10. In addition,
Gö6976 blocks the generation of active ADAM10. These results
demonstrated that furin, PC7 and PKCa were involved in the gen-
eration of active ADAM10. Accordingly, MT-III increased the
expression of PC7, furin, and PKCa, as precursor forms of ADAM10
are converted into the active forms by these enzymes. The active
form of ADAM10 affects the secretion of sAPPa during non-
amyloidogenic processing (Fig. 5).
4. Discussion
Cerebral amyloidosis plays a central role in the aetiopathogen-
esis of AD [25]. Several previous reports have demonstrated that
decreasing Ab generation/deposition by suppressing amyloido-
genic processing or promoting non-amyloidogenic processing
may be used to treat AD [26,27]. The proposed neuroprotective role
of MT-III was based on the following facts. In vitro data support a
neuroprotective effect of MT-III against Ab-induced neurotoxicity
A C
B
Fig. 2. MT-III increased the expression of furin and proprotein convertase7 (PC7) in N2a Swedish APP cells. Cells were pre-treated with increasing concentrations of MT-III (0,
1, 10 or 100 pM) for 24 h. (A and B) The cells were lysed and PC7 and furin mRNA levels were determined using real-time PCR. (C) Expression of furin and PC7 were analysed
by Western blotting of the cell lysates. Densitometry analysis of the band density ratio of furin/PC7 to b-actin. All experiments were performed in triplicate, and the means
and S.D.s are shown. ⁄P < 0.01; signiﬁcantly different from the control.
A
B C
Fig. 3. MT-III increased ADAM10 activation by furin and PC7 in N2a Swedish APP cells. Cells were preincubated for 1 h in the presence or absence of histatin 5 (furin/PC7
inhibitor) at the indicated concentrations. Cells were also incubated for 24 h in the presence or absence of 100 pM MT-III. (A) ADAM10 activation was analysed by Western
blotting of the cell lysates. Densitometry analysis of the band density ratio of active ADAM10 to precursor ADAM10. (B) The secretion level of sAPPawas analysed by Western
blotting of culture supernatant. (C) Ab level of the culture supernatant was determined by ELISA. All experiments were performed in triplicate, and the means and S.D.s are
shown. ⁄P < 0.01; signiﬁcantly different from the control.
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Fig. 4. MT-III increased ADAM10 activation by PKCa in N2a Swedish APP cells. Cells were pre-treated with MT-III as described above for 24 h. (A) Cells were lysed and the
PKCamRNA level was determined using real-time PCR. (B) Expression and phosphorylation of PKCa were analysed by Western blotting of cell lysates. Densitometry analysis
of the band density ratio of PKCa/phospho-PKCa to b-actin. (C) PKCa activation was analysed by Western blotting of the cell lysates. Densitometry analysis of the band
density ratio of phosphorylated PKCa to the PKCa. (D) The level of sAPPa secretion was analysed by Western blotting of the culture supernatant. (E) Ab level in the culture
supernatant was analysed by ELISA. All experiments were performed in triplicate, and the means and S.D.s are shown. ⁄P < 0.01; signiﬁcantly different from the control.
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against Ab toxicity; however, the role of MT-III in non-amyloido-
genic processing of APP remains unknown.
The non-amyloidogenic pathway is important because in most
cases the sAPPa increase is accompanied by a concomitant
decrease in Ab production [4,29–31]. Our ﬁndings clearly indicate
that MT-III increases sAPPa levels in N2a Swedish APP cells. We
also observed that MT-III treatment did not affect ADAM10
(a-secretase) and BACE1 (b-secretase) gene expression. However,
MT-III treatment signiﬁcantly increased concentration of the active
form of ADAM10 (Fig. 1D). ADAM10 activation is known to gener-
ate sAPPa and negates the pathological production of Ab [32].
Normally, a-secretase exists in two forms: precursor and active.
The former is the proenzyme form, which is latent and has little
enzymatic activity. Previous studies provided evidence that consti-
tutive a-secretase activity occurs on the cell surface and regulated
a-secretase activity takes place in trans-Golgi network, a major
locus for proprotein processing by PC7 and furin [15]. Overexpres-
sion of the PC7 and furin showed an increased ADAM10maturationin APP processing [20]. Previous studies demonstrated that PC7
and furin increase sAPPa secretion and generate active ADAM10
with a-secretase activities. We found that MT-III signiﬁcantly
increased PC7 and furin gene expression (Fig. 2). The increased
activation of a-secretase induced by overexpression of either PC7
or furin is accompanied by an increased a-secretase activity [20].
We conﬁrmed that PC7 and furin inhibition by histatin 5 negatively
affected MT-III-induced active ADAM10 generation (Fig. 3A).
One possible explanation for the uncertainty regarding localisa-
tion of a-secretase is that more than one enzyme may be involved
in the process. Although constitutive activity has not been
observed, a-secretase cleavage appears to be regulated by protein
kinase C (PKC). Direct activation of PKC by phorbol ester stimula-
tion was one of the earliest a-secretase activating stimuli to be
identiﬁed. In addition, several studies have shown that PKCa plays
a signiﬁcant role in APP processing and a-secretase activity regula-
tion [33–35]. Furthermore, it is known that the reduced PKC
activity in AD brain tissue may be attributed to alterations in
PKC protein [32]. PKCa and PKCb were demonstrated to be the
Fig. 5. Role of MT-III during non-amyloidogenic processing. APP can be cleaved in a non-amyloidogenic pathway. In the non-amyloidogenic pathway, APP is ﬁrst cleaved by
a-secretases (ADAM10). Processing by a-secretase generates sAPPa and a C-terminal membrane-bound fragment, C83, which is further cleaved by the c-secretase complex to
generate the peptide p3. In other words, MT-III increases the expression of PC7, furin, PKCa and phosphorylation of PKCa. ADAM10 is then activated by PC7, furin and PKCa.
Next, the active ADAM10 cleaves APP within the Ab domain, thus precluding the formation of Ab peptides.
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PKCc and d on APP processing are unclear. In this study, we
demonstrated that MT-III increased the secretion of sAPPa via
PKCa (Fig. 4C and D). Moreover, MT-III increased PKCa gene
expression in N2a Swedish APP cells. However, MT-III did not
increase the PKCb and PKCc gene expression.
MT-III is zinc-binding proteins involved in the regulation of the
transport, storage and transfer of zinc to various enzymes and tran-
scription factors [39]. Furthermore, a-secretase has been
characterised as zinc metalloproteases that cleaves APP. The pro-
tective effect of MT on Ab toxicity may be due to its ability of metal
modulation. Secretion of sAPPa by a-secretase is a highly regulated
second messenger pathway that involves several protein kinases,
including PKC, MAPK, and PI3K. Furthermore, activation of growth
factor receptors, such as epidermal growth factor, insulin/insulin-
like growth factor receptors and tyrosine receptor kinase B (TrkB)
are known to enhance the secretion of sAPPa through activation
of PKC and PI3K. Previous studies have shown that TrkA signalling
pathways in neural cells activate PKC and PI3K [36,37]. We have
demonstrated previously that MT-III activates the PI3K/Akt signal-
ling pathway through TrkA receptors. Although the precise
mechanisms by which MT-III prevents cell death via activation of
the TrkA signalling pathway remain unclear, our results increase
our understanding of non-amyloidogenic processing of APP by
MT-III. Future studies will explore the role of MT-III in non-amyloi-
dogenic processing of APP through the TrkA signalling pathway.
In summary, this study demonstrated a functional role for MT-
III in non-amyloidogenic processing. Taken together, our results
suggest that MT-III may direct APP processing towards the non-
amyloidogenic pathway by increasing ADAM10 activity, whichmay be used to identify novel therapeutic strategies for the treat-
ment of AD.
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